Ore-lax, a novel microemulsion-based gel containing oregano essential oil, is a promising topical formulation for muscle pain relief. Oregano essential oil is rich in carvacrol, a natural compound that exhibits antioxidant, anti-inflammatory, and anesthetic activities. Microemulsion technology is used to enhance both the physical and chemical stability of Ore-lax formulations. Microemulsions are thermodynamically stable systems which require no specific or sophisticated technology to be formulated. Therefore, low cost of production is one of the economic benefits of microemulsion at the industry level. In addition, large scale production is easily achievable. Ore-lax microemulsion with the small internal droplet size of around 180 nm can result in enhanced carvacrol efficacy, prolonged muscle pain relief, and non-irritation.
Ore-lax is suggested as a mild formulation for topical application since it exhibits no cytotoxic effect on the HaCaT keratinocyte cell line and possesses the ability to reduce the irritation effect of oregano essential oil. Ore-lax has undergone testing in 40 human volunteers for efficacy and satisfaction. Therefore, Ore-lax is suitable for people of almost all ages who encounter muscle pain from either office syndrome or excessive exercise.
The technology provider is seeking collaboration opportunities with partners who are interested to further develop Ore-lax and/or incorporate Ore-lax actives into enhanced product offerings for muscle pain relief.
Ore-lax is a microemulsion-based gel that contains oregano essential oil with nanoscale internal droplet size of about 180 nm, making it an attractive transparent gel.
Advantages of Ore-lax:
The global topical pain relief market size was valued at $8,864.0 million in 2019. It is projected to reach $12,219.7 million by 2027 at a CAGR of 5.2% from 2020 to 2027.
Potential applications of the technology: